Details Industries Biotechnology Health Care Medical Headquarters Regions Asia-Pacific (APAC), Australasia Founded Date 2001 Founders Mark Smythe Operating Status Active Last Funding Type Post-IPO Equity Legal Name Protagonist Therapeutics, Inc. Stock Symbol NASDAQ:PTGXProtagonist Therapeutics, Inc. (PTGX) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.05 +0.29 (+1.55%) At close: 04:00PM EDT 19.42 +0.37 (+1.94%) After hours: 06:46PM...Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and PN-235 in advanced stages of clinical development, both derived from the Company's ...Director, President & CEO, Protagonist Therapeutics. Dr. Patel has served as a member of the board of directors and as the President and Chief Executive Officer of Protagonist since December 2008. He has 33 years of executive, entrepreneurial, and scientific experience that span the pharmaceutical, biotechnology and biopharmaceutical industries.Protagonist Therapeutics. Market Cap. Today's Change. (2.09%) $0.40. Current Price. $19.53. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing ...Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company's ...Protagonist Therapeutics Inc. DEVELOPING LIFE-CHANGING PEPTIDE DRUG THERAPIES Welcome to Protagonist, a clinical-stage biopharmaceutical company.Protagonist Therapeutics published its third-quarter results on Nov. 3, reporting a net loss of roughly $33.8 million on revenue of $10.3 million. It closed out the quarter with cash and short ...Protagonist Therapeutics is currently working to tackle some serious issues with an underserved form of blood cancer. A recent cancer scare sent shockwaves through the company's valuation, and it ...Protagonist Therapeutics published its third-quarter results on Nov. 3, reporting a net loss of roughly $33.8 million on revenue of $10.3 million. It closed out the quarter with cash and short ...Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company's ...Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and PN-235 in advanced stages of clinical development, both derived from the Company's ...Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company's ...7003 Background: Polycythemia (PV) patients with hematocrit (HCT) levels > 45% are at an increased risk of thrombosis and are treated with therapeutic phlebotomy (TP) alone or in combination with cytoreductive agents. Current therapies are not effective in reaching a HCT < 45% or uniformly tolerated. Rusfertide (PTG-300) is a hepcidin mimetic being developed as a non-cytoreductive option to ...Protagonist Therapeutics Inc. DEVELOPING LIFE-CHANGING PEPTIDE DRUG THERAPIES Welcome to Protagonist, a clinical-stage biopharmaceutical company. elizabeth moviejoe burrow wallpapers Protagonist Therapeutics, Inc 2013 - 2022 9 years. Newark, CA and Brisbane, Australia Head of R&D Protagonist Therapeutics Feb 2016 - 2021 5 years. Newark, CA and Brisbane, Australia ...Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived ...Protagonist Therapeutics focuses on peptide-based drugs, primarily rusfertide, which is undergoing a Phase 3 trial for polycythemia vera. Find out why PTGX stock is a Buy.By Chris MacDonald, InvestorPlace Contributor Sep 17, 2021, 4:29 pm EDT. Amid some rather impressive volatility today, Protagonist Therapeutics (NASDAQ: PTGX) is one of the biggest stock market ...Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company's ...Protagonist Therapeutics ( PTGX) says the Food and Drug Administration plans to revoke its breakthrough designation for a blood cancer drug, and PTGX stock collapsed Thursday. The company ...Protagonist Therapeutics is a biopharmaceutical company that utilized a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet ...Protagonist Therapeutics is a biopharmaceutical company that utilized a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet ...Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address ...Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs. Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide, PN-943, and PN-235 in different stages of clinical development, all derived from the ...Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities (NCEs) in different stages of development, all derived from the Company's ...Protagonist Therapeutics (PTGX) prices its public offering of 5M shares at a public offering price of $20.00 per share.Gross proceeds are expected to be $100M.Underwriters a 30-day...The average twelve-month price prediction for Protagonist Therapeutics is $38.00 with a high price target of $41.00 and a low price target of $35.00. Learn more on PTGX's analyst rating history. Do Wall Street analysts like Protagonist Therapeutics more than its competitors? Analysts like Protagonist Therapeutics more than other Medical companies. short ride Protagonist Therapeutics Inc (NASDAQ:PTGX) received a letter from the FDA indicating the agency's intent to rescind Breakthrough Therapy Designation for the company's rusfertide product candidate ...Protagonist Therapeutics (PTGX) prices its public offering of 5M shares at a public offering price of $20.00 per share.Gross proceeds are expected to be $100M.Underwriters a 30-day...Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company's ...Apr 5, 2023 · Protagonist Therapeutics, Inc. NEWARK, CA / ACCESSWIRE / April 4, 2023 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced the pricing of its previously... Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based new chemical entities in different stages of clinical development, all derived from the Company's proprietary ...Protagonist Therapeutics, Inc. (PTGX) NasdaqGM - NasdaqGM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 19.05 +0.29 (+1.55%) At close: 04:00PM EDT. 19.42 +0.37 (+1.94%) After hours:... Horsham, Pa., May 30, 2017 ― Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today it has entered into a worldwide exclusive license and collaboration agreement with Protagonist Therapeutics, Inc. (Protagonist) to develop, manufacture and commercialize PTG-200, a first-in-class, oral interleukin-23 receptor (IL-23R) antagonist drug candidate ...Mar 7, 2023 · NEWARK, Calif., March 7, 2023 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company"), today announced positive topline results from its collaboration... Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived from the Company's proprietary technology platform.Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. boston children's hospital portal PN-943 is an orally stable, gastrointestinal-restricted peptide that binds specifically to α4ß7 integrin on leukocytes, blocking leukocyte trafficking to and activation in the gut, inhibiting colon inflammation and reducing signs and symptoms of active ulcerative colitis. Two pharmacokinetic/pharmac …Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived from the Company's proprietary technology platform.Protagonist Therapeutics is also developing PN-943, an oral alpha-4-beta-7 integrin antagonist, for the treatment of inflammatory bowel disease. The company plans to begin a phase II study on the ...Protagonist Therapeutics 3 Peptide-based Medicines Potency Peptide Ch emist ry SAR, L eads Phage Libr aries Hi ts Computati onal V ec rix, Clu s Vectrix Cl usters 1 2 3 PO TENC Y Oral Stability Peptid omimeti cs GI As says GI-Restrict ed Targeted GI a bsorption & de livery Systemic Avail ability Formula tion SAR, T ransp t 4 5 6 ST ABILITY ...Director, President & CEO, Protagonist Therapeutics. Dr. Patel has served as a member of the board of directors and as the President and Chief Executive Officer of Protagonist since December 2008. He has 33 years of executive, entrepreneurial, and scientific experience that span the pharmaceutical, biotechnology and biopharmaceutical industries.Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived ...Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company's ...Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and PN-235 in advanced stages of clinical development, both derived from the Company's ...Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived ...Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs.Tue., September 12, 2023 | MarketBeat. BVF Inc. IL bought a new stake in Protagonist Therapeutics, Inc. ( NASDAQ:PTGX - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 3,775,900 shares of the company's stock, valued at approximately $86,846,000.Protagonist Therapeutics skyrocketed 52% on March 7 after positive topline results from the FRONTIER 1 Phase 2b trial utilizing JNJ-2113. Read my take on PTGX. problem child 3 Protagonist Therapeutics, Inc. (PTGX) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.05 +0.29 (+1.55%) At close: 04:00PM EDT 19.42 +0.37 (+1.94%) After hours: 06:46PM...Protagonist Therapeutics ( PTGX) says the Food and Drug Administration plans to revoke its breakthrough designation for a blood cancer drug, and PTGX stock collapsed Thursday. The company ...NVIDIA Corporation Common Stock. $408.55 -15.33 -3.62%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers ...Protagonist Therapeutics, Inc 2013 - 2022 9 years. Newark, CA and Brisbane, Australia Head of R&D Protagonist Therapeutics Feb 2016 - 2021 5 years. Newark, CA and Brisbane, Australia ... all countries flags Protagonist Therapeutics ( PTGX) says the Food and Drug Administration plans to revoke its breakthrough designation for a blood cancer drug, and PTGX stock collapsed Thursday. The company ...Protagonist Therapeutics has raised a total of $389M in funding over 10 rounds. Their latest funding was raised on Jun 14, 2021 from a Post-IPO Equity round. Protagonist Therapeutics is registered under the ticker NASDAQ:PTGX . Their stock opened with $12.00 in its Aug 10, 2016 IPO. Protagonist Therapeutics is funded by 15 investors.By Chris MacDonald, InvestorPlace Contributor Sep 17, 2021, 4:29 pm EDT. Amid some rather impressive volatility today, Protagonist Therapeutics (NASDAQ: PTGX) is one of the biggest stock market ...Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived from the Company's proprietary technology platform.Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company's ...Protagonist’s Profile, Revenue and Employees. Protagonist is a California-based biopharmaceutical company that develops and commercializes peptide therapeutics for the treatment of gastrointestinal diseases. Protagonist’s primary competitors include OrphoMed, Phathom, Ardelyx and 9 more.About Protagonist Therapeutics Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived from the Company's proprietary technology platform. Protagonist scientists jointly discovered PN-235 (now known as JNJ ...NEWARK, Calif., Sept. 17, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced the receipt of a verbal communication from the U.S.... volaris check in Oct 4, 2021 · NEWARK, Calif., Oct. 4, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that an abstract highlighting new results from its Phase ... Rewarding Careers with Protagonist Therapeutics. Discovering and developing transformative peptide-based drug therapies—and getting them into the hands of patients who need them most—requires a diversity of talents, expertise, character traits, and personalities. We understand that our people are our greatest resource, and we create a work ...Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs.Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived from the Company's proprietary technology platform. evita movie Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product ...Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing ...Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs. yale smart lock Technology - Protagonist Therapeutics Inc. Developing More Effective Medicine: The Protagonist Approach to New Peptide Discoveries At Protagonist, our highly specialized team of technical experts have developed a proprietary technology platform that has led to numerous highly unique recipes in the field of peptide therapeutics.Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived ...Jun 3, 2021 · NEWARK, Calif., June 3, 2021 /PRNewswire/ -- Protagonist Therapeutics ("Protagonist" or "the Company") (Nasdaq: PTGX), today announced that the U.S. Food and Drug Administration (FDA) has granted ... Protagonist Therapeutics is a biopharmaceutical company that utilized a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet ...Shares of Protagonist Therapeutics (PTGX) have gained 9.1% over the past four weeks to close the last trading session at $28.72, but there could still be a solid upside left in the stock if short ...Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product ...Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived from the Company's proprietary technology platform.Protagonist Therapeutics focuses on peptide-based drugs, primarily rusfertide, which is undergoing a Phase 3 trial for polycythemia vera. Find out why PTGX stock is a Buy.Protagonist Therapeutics ( PTGX) says the Food and Drug Administration plans to revoke its breakthrough designation for a blood cancer drug, and PTGX stock collapsed Thursday. The company ...Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company's ...Protagonist Therapeutics has raised a total of $389M in funding over 10 rounds. Their latest funding was raised on Jun 14, 2021 from a Post-IPO Equity round. Protagonist Therapeutics is registered under the ticker NASDAQ:PTGX . Their stock opened with $12.00 in its Aug 10, 2016 IPO. Protagonist Therapeutics is funded by 15 investors.Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived from the Company's proprietary technology platform.About Protagonist . Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company's proprietary technology platform. q y Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company's ...Protagonist Therapeutics, Inc 2013 - 2022 9 years. Newark, CA and Brisbane, Australia Head of R&D Protagonist Therapeutics Feb 2016 - 2021 5 years. Newark, CA and Brisbane, Australia ...Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs. Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities (NCEs) in different stages of development, all derived from the Company's ...Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address ...Shares of Protagonist Therapeutics ( PTGX -1.41%) were plunging 26.3% as of 3:39 p.m. EDT on Monday. The big decline came after the company announced that the U.S. Food and Drug Administration has ...Protagonist Therapeutics (PTGX) prices its public offering of 5M shares at a public offering price of $20.00 per share.Gross proceeds are expected to be $100M.Underwriters a 30-day...Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities (NCEs) in different stages of development, all derived from the Company's ... john jay high school Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing ...NEWARK, Calif., Sept. 17, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced the receipt of a verbal communication from the U.S....Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities (NCEs) in different stages of development, all derived from the Company's ...About Protagonist Therapeutics Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived from the Company's proprietary technology platform. Protagonist scientists jointly discovered PN-235 (now known as JNJ ...Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based new chemical entities in different stages of clinical development, all derived from the Company's proprietary ...Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived ...Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived ...Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived from the Company's proprietary technology platform.Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address ...Protagonist Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume. Change versus previous month Short interest in Protagonist Therapeutics has recently increased by 2.02%, indicating that investor sentiment is decreasing. Previous NextProtagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs.7003 Background: Polycythemia (PV) patients with hematocrit (HCT) levels > 45% are at an increased risk of thrombosis and are treated with therapeutic phlebotomy (TP) alone or in combination with cytoreductive agents. Current therapies are not effective in reaching a HCT < 45% or uniformly tolerated. Rusfertide (PTG-300) is a hepcidin mimetic being developed as a non-cytoreductive option to ...Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company's ...Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address ...Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs. digisigner Oct 4, 2021 · NEWARK, Calif., Oct. 4, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that an abstract highlighting new results from its Phase ... 7003 Background: Polycythemia (PV) patients with hematocrit (HCT) levels > 45% are at an increased risk of thrombosis and are treated with therapeutic phlebotomy (TP) alone or in combination with cytoreductive agents. Current therapies are not effective in reaching a HCT < 45% or uniformly tolerated. Rusfertide (PTG-300) is a hepcidin mimetic being developed as a non-cytoreductive option to ...NEWARK, Calif., Sept. 17, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced the receipt of a verbal communication from the U.S....Protagonist Therapeutics, Inc 2013 - 2022 9 years. Newark, CA and Brisbane, Australia Head of R&D Protagonist Therapeutics Feb 2016 - 2021 5 years. Newark, CA and Brisbane, Australia ...Shares of Protagonist Therapeutics ( PTGX -1.59%) rose by 23.3% for the week, as of Thursday afternoon, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech ... livenettv Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs.Protagonist Therapeutics, Inc 2013 - 2022 9 years. Newark, CA and Brisbane, Australia Head of R&D Protagonist Therapeutics Feb 2016 - 2021 5 years. Newark, CA and Brisbane, Australia ...Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs. Protagonist Therapeutics, Inc. (PTGX) NasdaqGM - NasdaqGM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 19.05 +0.29 (+1.55%) At close: 04:00PM EDT. 19.42 +0.37 (+1.94%) After hours:... Protagonist Therapeutics has raised a total of $389M in funding over 10 rounds. Their latest funding was raised on Jun 14, 2021 from a Post-IPO Equity round. Protagonist Therapeutics is registered under the ticker NASDAQ:PTGX . Their stock opened with $12.00 in its Aug 10, 2016 IPO. Protagonist Therapeutics is funded by 15 investors.Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform.Protagonist Therapeutics, Inc. (PTGX) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.05 +0.29 (+1.55%) At close: 04:00PM EDT 19.42 +0.37 (+1.94%) After hours: 06:46PM... free slots with bonus and free spins download Oct 4, 2021 · NEWARK, Calif., Oct. 4, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that an abstract highlighting new results from its Phase ... Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address ...Mar 7, 2023 · NEWARK, Calif., March 7, 2023 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company"), today announced positive topline results from its collaboration... Shares of Protagonist Therapeutics (PTGX) have gained 9.1% over the past four weeks to close the last trading session at $28.72, but there could still be a solid upside left in the stock if short ...Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived ... mask cartoon Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived from the Company's proprietary technology platform.Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address ...By Chris MacDonald, InvestorPlace Contributor Sep 17, 2021, 4:29 pm EDT. Amid some rather impressive volatility today, Protagonist Therapeutics (NASDAQ: PTGX) is one of the biggest stock market ...Protagonist Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume. Change versus previous month Short interest in Protagonist Therapeutics has recently increased by 2.02%, indicating that investor sentiment is decreasing. Previous Next purple place Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived ...Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and PN-235 in advanced stages of clinical development, both derived from the Company's ...Protagonist Therapeutics is a biopharmaceutical company that utilized a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet ... free hogwarts legacy full game download By Chris MacDonald, InvestorPlace Contributor Sep 17, 2021, 4:29 pm EDT. Amid some rather impressive volatility today, Protagonist Therapeutics (NASDAQ: PTGX) is one of the biggest stock market ...Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs.Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based new chemical entities in different stages of clinical development, all derived from the Company's proprietary ...About Protagonist Therapeutics Protagonist Therapeutics is a privately held biotechnology company pursuing the discovery and development of disulfide rich peptides (DRPs) as well differentiated alternatives to antibodies and also as new chemical entities (NCEs) against those targets and diseases for which suitable small molecule and/or biologic ...Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived ...Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based new chemical entities in different stages of clinical development, all derived from the Company's proprietary ...The average twelve-month price prediction for Protagonist Therapeutics is $38.00 with a high price target of $41.00 and a low price target of $35.00. Learn more on PTGX's analyst rating history. Do Wall Street analysts like Protagonist Therapeutics more than its competitors? Analysts like Protagonist Therapeutics more than other Medical companies.Mar 15, 2023 · Protagonist Therapeutics (Nasdaq:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update. 7003 Background: Polycythemia (PV) patients with hematocrit (HCT) levels > 45% are at an increased risk of thrombosis and are treated with therapeutic phlebotomy (TP) alone or in combination with cytoreductive agents. Current therapies are not effective in reaching a HCT < 45% or uniformly tolerated. Rusfertide (PTG-300) is a hepcidin mimetic being developed as a non-cytoreductive option to ...Protagonist Therapeutics, Inc. (PTGX) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.05 +0.29 (+1.55%) At close: 04:00PM EDT 19.42 +0.37 (+1.94%) After hours: 06:46PM...Protagonist Therapeutics, Inc 2013 - 2022 9 years. Newark, CA and Brisbane, Australia Head of R&D Protagonist Therapeutics Feb 2016 - 2021 5 years. Newark, CA and Brisbane, Australia ... azcentral sports Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Yet to Catch Up With Its Share Price. (Simply Wall St.) +10.03%. Apr-04-23 10:45PM. Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock.Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived ...Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities (NCEs) rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both ...Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs.For Protagonist Therapeutics, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered ... virginia tech shooting victims By Chris MacDonald, InvestorPlace Contributor Sep 17, 2021, 4:29 pm EDT. Amid some rather impressive volatility today, Protagonist Therapeutics (NASDAQ: PTGX) is one of the biggest stock market ...Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs.Protagonist Therapeutics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume. Change versus previous month Short interest in Protagonist Therapeutics has recently increased by 2.02%, indicating that investor sentiment is decreasing. Previous NextAbout Protagonist . Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company's proprietary technology platform.Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived ...Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company's ... arlington highlands Protagonist Therapeutics skyrocketed 52% on March 7 after positive topline results from the FRONTIER 1 Phase 2b trial utilizing JNJ-2113. Read my take on PTGX.Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs.Protagonist Therapeutics. Market Cap. Today's Change. (2.09%) $0.40. Current Price. $19.53. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing ...Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived from the Company's proprietary technology platform.Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and PN-235 in advanced stages of clinical development, both derived from the Company's ...Protagonist Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI Jul. 06: JMP Securities Raises Protagonist Therapeutics' Price Target to $35 From $28, Keeps Market Outperform Rating MTProtagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing ...About Protagonist Therapeutics Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived from the Company's proprietary technology platform. Protagonist scientists jointly discovered PN-235 (now known as JNJ ... scarlettjane92 Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities rusfertide and JNJ-2113 (formerly PN-235) in advanced stages of clinical development, both derived ...Shares of Protagonist Therapeutics ( PTGX -1.41%) were plunging 26.3% as of 3:39 p.m. EDT on Monday. The big decline came after the company announced that the U.S. Food and Drug Administration has ...Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address ...Protagonist Therapeutics, Inc 2013 - 2022 9 years. Newark, CA and Brisbane, Australia Head of R&D Protagonist Therapeutics Feb 2016 - 2021 5 years. Newark, CA and Brisbane, Australia ...Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address ... surency flex Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs.Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based ...Original Story Published July 3. J&J’s Protagonist-Licensed Psoriasis Drug Falls Short in Phase II Trial . JNJ-2113, an oral psoriasis drug licensed from Protagonist Therapeutics and planned to be commercialized by Johnson & Johnson’s Janssen Biotech, is not as effective as some of its injectable competitors, according to the results of a Phase IIb clinical study shared Monday as an ...Protagonist Therapeutics is a biopharmaceutical company with multiple peptide-based new chemical entities in different stages of clinical development, all derived from the Company's proprietary ...